Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Femasys (NASDAQ:FEMY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.
Valuation & Earnings
This table compares Co-Diagnostics and Femasys’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $6.81 million | 5.55 | -$35.33 million | ($1.21) | -1.00 |
| Femasys | $1.07 million | 26.64 | -$14.25 million | ($0.92) | -1.40 |
Femasys has lower revenue, but higher earnings than Co-Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -518.69% | -35.37% | -32.58% |
| Femasys | -1,329.10% | -105.47% | -80.50% |
Institutional and Insider Ownership
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by insiders. Comparatively, 16.4% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for Co-Diagnostics and Femasys, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 0 | 1 | 0 | 0 | 2.00 |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
Co-Diagnostics presently has a consensus price target of $2.50, suggesting a potential upside of 106.61%. Femasys has a consensus price target of $11.33, suggesting a potential upside of 778.55%. Given Femasys’ stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Co-Diagnostics.
Volatility and Risk
Co-Diagnostics has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.76, indicating that its share price is 376% less volatile than the S&P 500.
Summary
Femasys beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Femasys
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
